The compound you've described, **2-(1-ethyl-4-oxo-3-furo[3,4]pyrrolo[3,5-c][1,2,4]triazinyl)-N-[4-(2-furanyl)butan-2-yl]propanamide**, is a complex organic molecule with a rather long and specific name.
While I can't provide a detailed explanation of its research significance without more context, I can offer some insights based on its chemical structure and potential applications:
**Key Features:**
* **Heterocyclic core:** The molecule contains several fused heterocyclic rings, including a furo[3,4]pyrrolo[3,5-c][1,2,4]triazine system. These rings often exhibit unique electronic and steric properties, making them valuable in drug development and materials science.
* **Functional groups:** The molecule possesses various functional groups like amides, ketones, and furan rings. These groups can contribute to the molecule's reactivity, solubility, and interactions with biological targets.
* **Chirality:** The presence of a chiral center (likely at the butan-2-yl moiety) suggests the molecule might exist as stereoisomers, potentially leading to different biological activities.
**Potential Research Applications:**
Given its complex structure and potential for modification, this compound could be of interest in various research areas, including:
* **Drug discovery:** The presence of the furo[3,4]pyrrolo[3,5-c][1,2,4]triazine system is often associated with biological activity. This molecule might possess pharmacological properties that could be investigated for therapeutic applications.
* **Materials science:** The unique electronic and steric properties of the heterocycles could make this compound suitable for developing novel materials with specific properties.
* **Chemical synthesis:** The molecule's complex structure could serve as a building block for the synthesis of other intricate compounds.
**To understand its true significance, you would need more information:**
* **Source:** Where did you encounter this compound? (e.g., a scientific publication, a patent, a database)
* **Context:** What was the specific research question or area of study?
* **Biological activity:** Does it have any known biological activity, such as enzyme inhibition or receptor binding?
With this additional context, it would be possible to provide a more informed and detailed explanation of its importance.
ID Source | ID |
---|---|
PubMed CID | 3244526 |
CHEMBL ID | 1387407 |
CHEBI ID | 107779 |
Synonym |
---|
2-(5-ethyl-8-oxofuro[2',3':4,5]pyrrolo[1,2-d][1,2,4]triazin-7(8h)-yl)-n-[3-(2-furyl)-1-methylpropyl]propanamide |
MLS000093993 , |
smr000029607 |
CHEBI:107779 |
AKOS001853641 |
HMS2172O22 |
CCG-141409 |
HMS3315A07 |
REGID_FOR_CID_3244526 |
bdbm38153 |
2-(1-ethyl-4-oxidanylidene-furo[3,4]pyrrolo[3,5-c][1,2,4]triazin-3-yl)-n-[4-(furan-2-yl)butan-2-yl]propanamide |
cid_3244526 |
2-(1-ethyl-4-oxofuro[3,4]pyrrolo[3,5-c][1,2,4]triazin-3-yl)-n-[4-(furan-2-yl)butan-2-yl]propanamide |
2-(1-ethyl-4-oxo-3-furo[3,4]pyrrolo[3,5-c][1,2,4]triazinyl)-n-[4-(2-furanyl)butan-2-yl]propanamide |
2-(1-ethyl-4-keto-furo[3,4]pyrrolo[3,5-c][1,2,4]triazin-3-yl)-n-[3-(2-furyl)-1-methyl-propyl]propionamide |
CHEMBL1387407 |
Q27186112 |
2-(12-ethyl-9-oxo-5-oxa-1,10,11-triazatricyclo[6.4.0.02,6]dodeca-2(6),3,7,11-tetraen-10-yl)-n-[4-(furan-2-yl)butan-2-yl]propanamide |
Class | Description |
---|---|
furopyrrole | Any organic heterobicyclic compound containing ortho-fused furan and pyrrole rings. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 3.5481 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 79.4328 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 17.7828 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 15.8489 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 10.4756 | 28.1838 | AID901 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 260.0000 | 0.1600 | 24.4900 | 236.5000 | AID435004 |
NPYLR7B | Aedes aegypti (yellow fever mosquito) | EC50 (µMol) | 0.7430 | 0.0390 | 2.2899 | 18.3000 | AID1259426 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |